The effectiveness of current antiretroviral therapies has led to more patients receiving long-term therapy, and increasing numbers of older patients. The complex interactions between HIV infection, ageing, comorbid conditions and drug-related toxicities, and their combined effects on patient health and quality of life, were the subject of the 11th International Workshop on Adverse Drug Reactions and Co-Morbidities in HIV. Key topics included the metabolic effects of antiretroviral agents, cardiovascular disease, bone metabolism and age-related changes in disease and response to drug therapy. Data presented at the meeting refect the growing recognition of common pathways that contribute to progression of mutiple types of disease and adverse drug reactions.
References
1.
MontessoriV., PressN., HarrisM., AkagiL., MontanerJ.S.Adverse effects of antiretroviral therapy for HIV infection.CMAJ2004; 170: 229–238.
2.
GrinspoonS., CarrA.Cardiovascular risk and body-fat abnormalities in HIV-infected adults.N Engl J Med2005; 352: 48–62.
3.
BacchettiP., GrunfeldC., HeymsfieldS.B.Intermuscular adipose tissue is decreased in HIV infection.Antivir Ther2009; 14 Suppl 2: A3.
4.
Study of Fat Redistribution and Metabolic Change in HIV Infection (FRAM).Fat distribution in men with HIV infection.J Acquir Immune Defic Syndr2005; 40: 121–131.
5.
Study of Fat Redistribution and Metabolic Change in HIV Infection (FRAM).Fat distribution in women with HIV infectionJ Acquir Immune Defic Syndr2006; 42: 562–571.
6.
PulsR.L., SrasuebkulP., PetoumenosK., EmeryS., CooperD.A.Anthropometric and metabolic outcomes in a 48-week randomized, open-label study of three different combination antiretroviral regimens as initial therapy for HIV infection.Antivir Ther2009; 14 Suppl 2: A8.
7.
IonescuG., WalkerR., HeQ., AlbuJ.B., EngelsonE.S., KotlerD.P.Effect of substituting tenofovir for zidovudine versus continuing zidovudine on physiological correlates of mitochondrial function in HIV-infected subjects on nucleoside reverse transcriptase inhibitor therapy (NRTI)-based highly active antiretroviral therapy (HAART) – final report.Antivir Ther2009; 14 Suppl 2: A17.
8.
VrouenraetsS.M.E., Fernandez GarciaE., JacksonA.Both once-daily saquinavir/ritonavir and atazanavir/ritonavir, when combined with tenofoviar/emtricitabine conserve adipose tissue, only modestly affect lipids and exhibit similar mild reduction in glomerular filtration over 48 weeks: the BASIC trial.Antivir Ther2009; 14 Suppl 2: A27.
9.
PodzamczerD., SorianoV., Andrade-VillanuevaJ.Comparison of lipid profile with nevirapine versus atazanavir/ritonavir, both combined with tenofovir DF and emtricitabine (TDF/FTC), in treatment-naive HIV-1-infected patients: ARTEN study week 48 results.Antivir Ther2009; 14 Suppl 2: A51.
10.
AlamN.M., Cortina-BorjaM., GoetghebuerT., ViganoA., ThorneC.Risk factors for body fat redistribution in a European cohort of HIV-infected children and adolescents.Antivir Ther2009; 14 Suppl 2: A27.
11.
GathercoleL.L., TomlinsonJ.W., BoothbyM.Changes in the adipocyte (lipid and glucose metabolism) gene expression following 18–24 months treatment with ZDV or TDF-containing ART; and adipocyte mitochondrial gene expression.Antivir Ther2009; 14 Suppl 2: A9.
12.
McGeeK.C., BoothbyM., TomlinsonJ.W.Adipocyte mitochondrial gene expression following 18–24 months treatment with zidovidine or tenofovir-containing antiretroviral therapy.Antivir Ther2009; 14 Suppl 2: A10.
13.
DistlerO., MallonP.W., KelleherA.D., CarrA., CalmyA., CooperD.A.Evaluation of adipose gene expression and mitochondrial DNA in healthy adults over a 6 week course of NRTI and/or PI treatment. Indications of divergent effects.Antivir Ther2009; 14 Suppl 2: A10.
14.
MartoneS., MilazzoL., CellerinoP.mRNA expression profile of adipocytes cells in HIV-1-positive with HAART-related lipodistrophy.Antivir Ther2009; 14 Suppl 2: A23.
15.
StankovM.V., SchmidtR.E., BehrensG.M.N.Combined impact of C-reactive protein and stavudine on adipogenesis.Antivir Ther2009; 14 Suppl 2: A11.
16.
YuanG., ChenX., MaQ.C-reactive protein inhibits adiponectin gene expression and secretion in 3T3-L1 adipocytes.J Endocrinol2007; 194: 275–281.
17.
ShikumaC.M., GerschensonL.E., KruseC.A.Pre-adipocyte apoptosis and macrophages in subcutaneous adipose tissue contribute to HIV-associated lipoatrophy.Antivir Ther2009; 14 Suppl 2: A23.
18.
VelosoS., SirventJ.J., López-DuplaM.Subcutaneous adipose tissue adipocyte apoptotic parameters in HIV-1-infected patients with HAART-related lipoatrophy.Antivir Ther2009; 14 Suppl 2: A24.
19.
LoJ., YouS.M., WeiJ., CanavanB., GrinspoonS.Relationship of peak growth hormone to cardiovascular parameters, waist circumference, lipids and glucose in HIV-infected patients and healthy adults.Clin Endocrinol (Oxf)2009; 71: 815–822.
20.
LoJ., YouS.M., LiebauJ.Effects of treatment and discontinuation of low dose physiologic growth hormone in HIV patients with abdominal fat accumulation: a randomized, placebo-controlled 36-month crossover trial.Antivir Ther2009; 14 Suppl 2: A3.
21.
FalutzJ., MamputuJ-C, Potvin SoulbanG., GrinspoonS.Metabolic effects of tesamorelin (TH9507), a growth hormone-releasing factor analogue, in HIV-infected patients with excess abdominal fat. a pooled analysis of 2 multicenter, double-blind placebo-controlled Phase 3 trials with 816 randomized patients.18th Annual Canadian Conference on HIV/AIDS Research. 23–26 April 2009, Vancouver, BC, Canada. Abstract O070.
22.
TurnerR.R., McCollS.L., FalutzJ.The impact and clinical relevance of tesamorelin (TH9507), a growth hormone-releasing factor analogue, on belly and weight image and healthrelated quality of life (HRQOL) in HIV-infected patients with excess abdominal fat: a combined analysis of two Phase III studies.Antivir Ther2009; 14 Suppl 2: A4.
23.
BastardJ-P, BouteloupV., LeportC.High incidence and risk factors for diabetes over the 9-year follow-up after first generation protease inhibitors’ initiation in the ANRS CO8 APROCO-COPILOTE cohort.Antivir Ther2009; 14 Suppl 2: A5.
24.
BrownT.T., TassiopoulosK., ShikumaC., McComseyG.A.Higher markers of TNF-α activity 48 weeks after ART-initiation are associated with incident diabetes mellitus in the ACTG/ALLRT cohort: a nested case-control study.Antivir Ther2009; 14 Suppl 2: A6.
25.
KimP.S., WoodsC., DutcherL.Increased microalbuminuria in HIV-infected adults with diabetes is associated with abacavir and viral load.Antivir Ther2009; 14 Suppl 2: A7.
26.
SchusterI., ThöniG.J., EdéryS.Subclinical cardiac abnormalities in human immunodeficiency virus-infected men receiving antiretroviral therapy.Am J Cardiol2008; 101: 1213–1217.
27.
HruzP.W., YanQ., StruthersH., JayP.Y.HIV protease inhibitors that block GLUT4 precipitate acute, decompensated heart failure in a mouse model of dilated cardiomyopathy.FASEB J2008; 22: 2161–2167.
28.
VyasA.K., YangK-C, WooD., JayP.Y., HruzP.W.Beneficial effect of exenatide on glucose homeostasis and survival in ritonavir-treated mice with advanced dilated cardiomyopathy.Antivir Ther2009; 14 Suppl 2: A7.
29.
FleischmanA., JohnsenS., SystromD.M.Effects of a nucleoside reverse transcriptase inhibitor, stavudine, on glucose disposal and mitochondrial function in muscle of healthy adults.Am J Physiol Endocrinol Metab2007; 292: E1666–E1673.
30.
SaeediR., SaranV., JohnsK.Stavudine alters expression of adipocyte-derived adipocytokines and promotes insulin resistance in cultured adipocytes.Antivir Ther2009; 14 Suppl 2: A25.
31.
GanzP.Non-invasive assessment of atherosclerosis – are measurements of endothelial function and carotid IMT useful?11th International Workshop on Adverse Drug Reactions and Co-morbidities in HIV. 26–28 October 2009, Philadelphia, PA, USA. Available from http://broadcast.sztream.com/1515174/lipo2009/Index.html.
32.
LudmerP.L., SelwynA.P., ShookT.L.Paradoxical vasoconstriction induced by acetylcholine in atherosclerotic coronary arteries.N Engl J Med1986; 315: 1046–1051.
33.
GuaraldiG., ZonaS., OrlandoG.Progression of subclinical atherosclerosis in HIV-infected patients.Antivir Ther2009; 14 Suppl 2: A11.
34.
RichardsonR., SinnK., CooperD.A., PattS., CarrA.Arterial stiffness and cardiovascular biomarkers in HIV-infected adults.Antivir Ther2009; 14 Suppl 2: A12.
35.
YoungB., VanigT., DeJesusE.Framingham risk and lipoprotein changes after 24 weeks of treatment with abacavir/lamivudine (ABC/3TC) and raltegravir (RAL) in antiretroviral (ARV)-naive HIV-1-infected subjects.Antivir Ther2009; 14 Suppl 2: A54.
36.
HilemanC.O., CarmanT.L., GripshoverB.M.Salsalate is poorly tolerated and fails to improve endothelial function and insulin resistance in virologically suppressed HIV-infected patients.Antivir Ther2009; 14 Suppl 2: A13.
37.
LipshultzS.E., EasleyK.A., OravE.J.Cardiovascular status of infants and children of women infected with HIV-1 (P2C2 HIV): a cohort study.Lancet2002; 360: 368–373.
38.
CadeW.T., HollandM.R., StephensA.S.Decreased myocardial longitudinal strain in HIV-negative neonates exposed to HIV and HAART in utero.Antivir Ther2009; 14 Suppl 2: A13.
39.
RaderD.Inflammation and atherosclerosis. Presented at: 11th International Workshop on Adverse Drug Reactions and Co-morbidities in HIV. 26–28 October 2009, Philadelphia, PA, USA.
40.
CotterE.J., ChewN., PowderlyW.G., DoranP.P.Ex vivo infection of mesenchymal stem cells by HIV-1 alters differentiation potential and cell phenotype.Antivir Ther2009; 14 Suppl 2: A14.
41.
MoyleG., GivensN., PearceH., CompstonJ.Effects of ART on bone turnover markers and bone density in HIV-infected patients.Antivir Ther2009; 14 Suppl 2: A14.
42.
GallantJ.E., StaszewskiS., PozniakA.L.Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial.JAMA2004; 292: 191–201.
43.
WelzT., ChildsK., IbrahimF., PoultonM., PostF.Efavirenz use is associated with severe vitamin D deficiency in a large, ethnically diverse urban UK HIV cohort.5th IAS Conference on HIV Pathogenesis, Treatment and Prevention. 19–22 July 2009, Cape Town, South Africa. Abstract TUPEB186.
44.
BrownT.T., McComseyG.A.Association between initiation of antiretroviral therapy with efavirenz and decreases in 25-hydroxyvitamin D.Antivir Ther2009; 14 Suppl 2: A15.
45.
EffrosR.B., GrahamL.S., ParhamiF., TintutY.T-lymphocytes and bone loss in HIV disease: role of chronic stimulation and oxidized lipids.Antivir Ther2009; 14 Suppl 2: A16.
46.
FalutzJ., RosenthallL.FRAX score: fracture risk assessment in treated HIV patients.Antivir Ther2009; 14 Suppl 2: A31.
47.
GuaraldiG., ZonaS., VesciniF.Gender and gonadal function differences in the prevalence of bone mass reduction.16th Conference on Retroviruses and Opportunistic Infections. 8–11 February 2009, Montreal, QC, Canada. Abstract 754.
48.
LiuA., GvetadzeR., SellmeyerD., GrohskopfL., BuchbinderS.Low bone density among a population of healthy HIV-negative MSM screening for a pre-exposure prophylaxis trial.XVII International AIDS Conference. 3–8 August 2008, Mexico City, Mexico. Abstract THPE0169.
49.
GloverE., MartinJ., MocellinN.J., ElstonD., SmaillF., TarnopolskM.A.Exercise capacity and markers of mitochondrial function in HIV-infected patients on NRTI therapy.Antivir Ther2009; 14 Suppl 2: A61.
50.
HulganT., HaubrichR., RiddlerS.Mitochondrial DNA haplogroups and metabolic changes during antiretroviral therapy (ART) in AIDS Clinical Trials Group (ACTG) Study A5142.Antivir Ther2009; 14 Suppl 2: A17.
51.
Arenas-PintoA., WellerI., EkongR.Dideoxynucleoside-induced severe hyperlactataemia in white Europeans appears not to be caused by a common inherited mtDNA mutation.Antivir Ther2009; 14 Suppl 2: A65.
Blas-GarcíaA., VictorV.M., Gómez-SolerM., Gómez-SucerquiaL.J., ApostolovaN., EspulguesJ.V.EFV-induced reduction of mitochondrial respiration is due to the inhibition of complex I.Antivir Ther2009; 14 Suppl 2: A61.
54.
CampisiJ.Ageing: the ultimate co-morbidity factor. Presented at: 11th International Workshop on Adverse Drug Reactions and Co-morbidities in HIV. 26–28 October 2009, Philadelphia, PA, USA. Available from http://broadcast.sztream.com/1515174/lipo2009/Index.html.
55.
CotterE.J., PowderlyW.G., DoranP. P.. Tenofovir putatively induces fibrosis in cultured human proximal tubule epithelial cells.Antivir Ther2009; 14 Suppl 2: A18.
56.
BrownT.T., PatilS.P., JacobsonL.P.Association between systemic inflammation and obstructive sleep apnea in men with or at risk for HIV infection from the Multicenter AIDS Cohort Study (MACS).Antivir Ther2009; 14 Suppl 2: A19.
57.
JahanshadN., ShikumaC.M., KallianpurK., NakamotoB., ValcourV.G., ThompsonP.M.Impact of cerebrovascular risk factors on brain function and structure in HIV-infected individuals.Antivir Ther2009; 14 Suppl 2: A5.
58.
BiggarR.Does immunity control the expression of cancer? Learning from the experience of the HIV/AIDS epidemic. Presented at: 11th International Workshop on Adverse Drug Reactions and Co-morbidities in HIV. 26–28 October 2009, Philadelphia, PA, USA. Available from http://broadcast.sztream.com/1515174/lipo2009/Index.html.
59.
SarrazinC.New antiviral drugs against HCV – adverse event profiles and pharmacokinetic interactions. Presented at: 11th International Workshop on Adverse Drug Reactions and Co-morbidities in HIV. 26–28 October 2009, Philadelphia, PA, USA. Available from http://broadcast.sztream.com/1515174/lipo2009/Index.html.
